Table 1 |
||||
|
Biologicals and targets that are used or potentially may be used in primary Sjögren's syndrome |
||||
|
Target |
Biological |
Structure |
Results trials |
References |
|
|
||||
|
TNFα |
Infliximab |
Chimeric IgG1 mAb |
No effect in RCT |
[15] |
|
TNFα |
Etanercept |
TNF-Rec1-Fc IgG1 fusion protein |
No effect in (small-size) RCT |
|
|
IFNα |
Recombinant IFNα2a |
Increase in unstimulated whole saliva flow (RCT) |
[32] |
|
|
IFNα |
Rontalizumab |
Recombinant human mAb |
Not performed |
|
|
CD20 B cells |
Rituximab |
Chimeric IgG1 mAb |
Subjective and objective improvement of salivary flow (RCT), decrease in fatigue (RCT) |
|
|
CD22 B cells |
Epratizumab |
Recombinant human mAb |
Increase in unstimulated whole saliva, decrease in fatigue |
[45] |
|
BAFF |
Belimumab |
Recombinant human mAb |
In progress |
|
|
BAFF |
Atacicept |
TACI-Fc IgG1 fusion protein |
Not performed |
|
|
BAFF |
Briobacept |
BAFF-Rec-Fc IgG1 fusion protein |
Not performed |
|
|
CD28-mediated co-stimulation |
Abatacept |
CTLA4-Fc IgG1 fusion protein |
In progress |
|
|
|
||||
|
BAFF, B-cell activating factor; CTLA4, cytotoxic T-lymphocyte antigen 4; mAb, monoclonal antibody; RCT, randomized controlled trial; Rec, receptor; TACI, transmembrane activator and calcium-modulating cyclophilin ligand interactor. |
||||
|
Kallenberg et al. Arthritis Research & Therapy 2011 13:205 doi:10.1186/ar3234 |
||||